Zantac 75 Efferdose could challenge Alka-Seltzer as leading effervescent stomach remedy.
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC 75 EFFERDOSE COULD CHALLENGE ALKA-SELTZER as the top effervescent OTC stomach remedy, following FDA's recent approval of Glaxo Wellcome's NDA for the effervescent tablet version of 75 mg ranitidine. Zantac 75 Efferdose is the first approved nonprescription effervescent H2 antagonist. FDA cleared the product for OTC marketing on Feb. 26, the day of the agency's original user fee goal ("The Tan Sheet" March 2, p. 1). Warner- Lambert, which markets Zantac 75, also will market the effervescent tablets.